Exciting Developments from Addex Therapeutics
Addex Therapeutics (SWX: ADXN), a dynamic biopharmaceutical company with a focus on neurological disorders, has recently made noteworthy advancements in the treatment of chronic cough. Their innovative approach centers around a gamma-aminobutyric acid subtype B receptor (GABAB) positive allosteric modulator (PAM), which has exhibited promising anti-tussive activity in various preclinical models.
Clinical Insights from Recent Research
In preclinical studies, the GABAB PAM drug candidate has shown a remarkable ability to diminish cough frequency triggered by citric acid. This reduction was complemented by an increase in cough latency, indicating its potential effectiveness. What sets this candidate apart is its performance compared to traditional treatments like nalbuphine, baclofen, and codeine, where it has demonstrated superior tolerability and therapeutic margins.
Presentation of Results at the Upcoming Conference
Excitement surrounds the upcoming presentation at a major cough conference, slated to showcase these significant findings. Dr. Mikhail Kalinichev, Head of Translational Science at Addex, will discuss the compelling data on June 7, emphasizing the promising nature of this GABAB PAM drug candidate as we venture into further studies and clinical trials.
Statements from Addex's Leadership
Dr. Kalinichev expressed enthusiasm, stating that the data collected so far reflects the therapeutic potential of their selective GABAB PAM. He emphasized the need for better treatments for chronic cough, which presents ongoing challenges for many patients. As the data indicates, this candidate could represent a pioneering once-daily treatment option that could significantly benefit patients with refractory chronic cough.
The Allosteric Modulator Approach
The GABAB receptor plays a vital role in cough regulation, with existing treatments demonstrating various side effects and limitations. By focusing on an allosteric modulation, Addex aims to offer higher selectivity and reduced tolerance, enhancing patient outcomes.
About Addex Therapeutics
Addex Therapeutics is at the forefront of clinical-stage biopharmaceutical development, specializing in innovative small molecule allosteric modulators. Their lead candidate, the negative allosteric modulator dipraglurant, is under evaluation for recovery following brain injuries. Furthermore, Addex is engaged in a collaboration with Indivior to develop a GABAB PAM candidate for substance use disorders, successfully passing initial studies.
Contact Information for Inquiries
For those interested in further information about Addex Therapeutics, the following contacts are available:
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Email: PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
Telephone: +44 (0)7968 022075
Email: msinclair@halsin.com
Frequently Asked Questions
What is the significance of the GABAB PAM candidate?
The GABAB PAM candidate is significant due to its robust anti-tussive activity, demonstrating a potential breakthrough in treating chronic cough.
How was the GABAB PAM evaluated in preclinical studies?
It was evaluated in models that induced cough, showing a reduction in cough frequency and an increase in cough latency without tolerance.
Who presented the GABAB PAM findings, and when?
Dr. Mikhail Kalinichev presented the findings, with the presentation scheduled for June 7 at a prominent conference focused on cough management.
What advantages does the allosteric modulation approach offer?
Allosteric modulation can provide higher selectivity and better tolerability than traditional agonists, potentially leading to improved treatment outcomes.
Where can I find more information about Addex Therapeutics?
For more information, visit Addex Therapeutics' official website at www.addextherapeutics.com.
